top of page
Dr Jason Cafer's Psychopharmacology: Visualize to Memorize Medication Mascots

CYP2C9

​

“To See Nice(ly)”

​

For psychiatry, 2C9 interactions are of little clinical significance.

​

0% of individuals are 2C9 ultrarapid metabolizers. 5% are poor metabolizers

​

Conclusion: Consider checking valproic acid (VPA) levels more often if the patient is taking or stops taking enzalutamide, rifampin, or fluconazole, but don’t expect much variance from baseline. Consider avoiding paroxetine entirely.

CYP2C9 inducer mnemonics by Dr Jason Cafer MD psychopharmacology

There are no strong 2C9 inducers.

CYP2C9 interaction mnemonics inhibitors by Dr Jason Cafer MD psychopharmacology

There are no strong 2C9 inhibitors.

CYP2C9 inducers luminal phenobarbital rifampin enzalutamide by Dr Jason Cafer MD psychopharmacology
CYP2C9 inhibitors paxil paroxetine difulcan fluconazole nolvadex tamoxifen by Dr Jason Cafer MD psychopharmacology
CYP2C9 substrates interaction mnemonics by Dr Jason Cafer MD psychopharmacology dilantin phenytoin depakote valproate
2C9 substrates micronase glyburide glucotrol glipizide amaryl glimepiride orinase tolbutamide by Dr Jason Cafer MD psychopharmacology
CYP2C9 substrates coumadin warfarin lescol fluvastatin cozaar losartan celebrex celecoxib feldene piroxicam addyi flibanserin by Dr Jason Cafer MD psychopharmacology
bottom of page